Immune microenvironment and intrinsic subtyping in hormone receptor-positive/HER2-negative breast cancer

Source : https://www.nature.com/articles/s41523-021-00223-x

Little is known regarding the interaction between immune microenvironment and tumor biology in hormone receptor (HR)+/HER2− breast cancer (BC). We here assess pretreatment gene-expression data from 66 HR+/HER2− early BCs...

Patterns of treatment with everolimus exemestane in hormone receptor-positive HER2-negative metastatic breast cancer in the era of targeted therapy

Source : https://breast-cancer-research.biomedcentral.com/articles/10.1186/s13058-021-01394-y

Background There is currently no clinical trial data regarding the efficacy of everolimus exemestane (EE) following prior treatment with CDK4/6 inhibitors (CDK4/6i). This study assesses the use and efficacy of...

CDK4/6 inhibitors induce replication stress to cause long-term cell cycle withdrawal

Source : https://www.biorxiv.org/content/10.1101/2021.02.03.428245v1.abstract

CDK4/6 inhibitors arrest the cell cycle in G1-phase. They are approved to treat breast cancer and are also undergoing clinical trials against a range of other tumour types. To facilitate...

ERK inhibitor LY3214996-based treatment strategies for RAS-driven lung cancer

Source : https://mct.aacrjournals.org/content/early/2021/02/03/1535-7163.MCT-20-0531.abstract

RAS gene mutations are the most frequent oncogenic event in lung cancer. They activate multiple RAS-centric signaling networks among them the MAPK, PI3K and RB pathways. Within the MAPK pathway...

Ribociclib and Abemaciclib: CDK4/6 Inhibitors for the Treatment of Hormone Receptor-Positive Metastatic Breast Cancer

Source : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7844194/

The treatment landscape of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer has been modernized by the identification of cyclin-dependent kinase 4 and 6 (CDK4/6)...